JNJ-89853413

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameJNJ-89853413

Drug Alias NameCD33xVδ2 T-Cell Engager (Janssen)JNJ-89853413

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Myeloid cell surface antigen CD33Anti-TRDV2

TargetsMyeloid cell surface antigen CD33T cell receptor delta variable 2

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited KingdomSpain

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJanssen Research & Development Llc

China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A